If they are experienced using bisantrene it does rather narrow down who they could be or they are very old.
The key to valuing bisantrene is to treat it as effectively two different drugs:
1. A better anthracycline (eg doxorubicin, etc). There is real value here comes from the anthracyclines not being nice drugs which have some serious long term problems especially to the heart. Bisantrene is used at high doses (250mg/m2/day) to kill the cancer via DNA damage and Topo II inhibition (standard chemo). There is lots of clinical data supporting the use of bisantrene this way.
2. A FTO targeted agent. The value here comes from using bisantrene at a low dose to inhibit the FTO protein. The FTO protein appears to be overexpressed in a wide range of different cancers and its inhibition is a very exciting new target in oncology. There is no clinical data support the use bisantrene this way, but the preclinical data is very encouraging.
If they are experienced using bisantrene it does rather narrow...
- There are more pages in this discussion • 19,185 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.37 |
Change
-0.020(1.44%) |
Mkt cap ! $227.0M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.45 | $1.37 | $137.3K | 98.69K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 165 | $1.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 7611 | 1 |
View Market Depth
| Last trade - 16.10pm 19/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.38 |
Change
-0.020 ( 4.43 %) |
||||
| Open | High | Low | Volume | ||
| $1.43 | $1.44 | $1.38 | 5981 | ||
| Last updated 15.59pm 19/04/2024 ? | |||||
| RAC (ASX) Chart |